RxDoctor Payments Data

Jorge Rodriguez, PA

Medical · Sonora, CANPI 1225111750

Payments from drug & device makers

$475in general payments, 2019–2025

Across 17 payments — averaging $27.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$241
  • Lilly USA, LLC$60
  • AstraZeneca$44
  • Philips North America LLC$44
  • AbbVie$34
  • Alkermes, Inc.$22
  • plus $29 from 2 others

What the payments were for

  • Food & beverage$43091%
  • Education$459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$475 in reported general payments places this provider in the 50th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$108
Medicare patients
11
Services billed
11

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide39$36,220
JardianceEmpagliflozin11$16,841
EliquisApixaban14$14,252
Combivent RespimatIpratropium/Albuterol Sulfate23$11,442
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$9,661
Breo ElliptaFluticasone/Vilanterol17$8,665
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen207$5,108
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,653
Albuterol Sulfate HfaAlbuterol Sulfate62$1,921
Ergotamine-CaffeineErgotamine Tartrate/Caffeine12$1,599
Atorvastatin Calcium183$1,592
Ventolin HfaAlbuterol Sulfate18$1,356
Gabapentin84$1,309
Losartan Potassium142$1,223
Quetiapine Fumarate15$1,157

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$241$36,22039 claims
GSKTrelegy Ellipta, Breo Ellipta$14$18,32629 claims
Lilly USA, LLCHumulin N$60$48011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,087 medical providers in California.

Other medical in Sonora

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →